Fosamax Osteonecrosis of the Jaw Prognosis: Long term outcome of Osteonecrosis of the Jaw after Fosamax

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Science to Targeted Clinical Concern

The legacy of general health and science information has long provided a foundational understanding of how medications interact with the body over time. Within this broad context, the focus on bone health and the management of conditions such as osteoporosis has been a significant area of inquiry. This heritage established the importance of monitoring long-term therapeutic outcomes and recognizing potential adverse effects associated with pharmaceutical interventions. As this knowledge base matured, attention naturally shifted from broad population health metrics to more specific, patient-centered outcomes, particularly those involving rare but serious complications. One such area of concern emerged from the widespread use of bisphosphonates, notably Fosamax, for osteoporosis treatment. Reports of osteonecrosis of the jaw in patients receiving this therapy prompted a reevaluation of risk-benefit profiles.

Bridging to Occupational Exposure

This pivot from general health education to a targeted clinical concern now raises a parallel question: how do these established risks translate into settings where exposure is not merely therapeutic but occupational? The transition from patient care to workplace safety requires examining whether individuals involved in the manufacturing, handling, or administration of such compounds face distinct exposure patterns that could influence long-term prognosis. Thus, the legacy of general health science provides the necessary framework to now explore occupational exposure as a distinct variable in understanding the trajectory of osteonecrosis of the jaw following Fosamax use.

Fosamax and Osteonecrosis of the Jaw: Evidence and Risk Factors

Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). A known adverse effect associated with bisphosphonate use, including Fosamax, is osteonecrosis of the jaw (ONJ). ONJ is a condition involving exposed bone in the maxillofacial region that can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The condition has been reported in patients taking bisphosphonates, including Fosamax and Fosamax Plus D (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The prognosis for patients who develop ONJ after Fosamax exposure varies. According to the prescribing information, the time to onset of symptoms ranged from one day to several months after starting the drug. Most patients experienced relief of symptoms after stopping the medication. However, a subset of patients had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This suggests that while discontinuation often leads to improvement, re-exposure can trigger a relapse, indicating a persistent vulnerability in some individuals. The long-term outcome of ONJ is influenced by several risk factors. Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with longer duration of exposure to bisphosphonates. For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Population-Level Data and Mechanistic Insights

Population-level data provide additional context on prognosis. A cohort study among cancer-free female patients aged 40-89 with or at risk for osteoporosis in the United Kingdom Clinical Practice Research Datalink found that ONJ risk was threefold higher after 2-3 years of treatment and eightfold higher after 10 years compared with past use. Absolute risks remained low, approximately 0.05% after 5 years, and diminished after discontinuation (https://pubmed.ncbi.nlm.nih.gov/39400702/). This indicates that while the risk increases with longer exposure, the absolute risk is small, and the prognosis improves after stopping the drug, with risk levels declining over time. Mechanistic pathways linking Fosamax to ONJ involve the drug's effects on bone remodeling. Bisphosphonates like alendronate inhibit osteoclast-mediated bone resorption, which can lead to suppressed bone turnover. A multiscale characterization of jawbone provides comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). This research suggests that the unique structure and physiology of the jawbone may make it particularly susceptible to the effects of bisphosphonates, contributing to the development of ONJ.

Adequacy of Warnings and Timeline of Harm

Regarding the adequacy of warnings, the prescribing information for Fosamax includes a specific section on osteonecrosis of the jaw (Section 5.4) that describes the condition, associated risk factors, and management recommendations (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56; https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The label advises discontinuation if severe symptoms develop and notes that most patients have relief after stopping. It also warns that a subset may experience recurrence upon rechallenge. The label for Fosamax Plus D similarly lists risk factors and notes that discontinuation before invasive dental procedures may reduce risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). These warnings provide clinicians with information to assess risk and manage patients. The timeline between exposure and documented harm varies. Symptoms can appear as early as one day after starting the drug or may take several months to develop (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The risk increases with longer duration of use, with notable elevations after 2-3 years and more substantially after 10 years (https://pubmed.ncbi.nlm.nih.gov/39400702/). This suggests that both short-term and long-term exposures carry some risk, but the probability of harm grows with cumulative exposure.

Summary of Prognosis and Clinical Considerations

In summary, the prognosis for ONJ after Fosamax use is generally favorable upon drug discontinuation, with most patients experiencing symptom relief. However, risk factors such as invasive dental procedures, cancer, concomitant therapies, and poor oral hygiene can worsen outcomes. The risk of ONJ increases with longer treatment duration, but absolute risks remain low. Warnings in the prescribing information adequately describe these risks and management strategies. Clinicians should consider these factors when prescribing Fosamax and monitoring patients for potential adverse effects.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the long-term prognosis for osteonecrosis of the jaw after stopping Fosamax?

The prognosis is generally favorable upon discontinuation, with most patients experiencing relief of symptoms. However, a subset may have recurrence if rechallenged with the same or another bisphosphonate. Risk factors like invasive dental procedures, cancer, and poor oral hygiene can worsen outcomes. Absolute risk remains low, with risk levels declining after stopping the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56; https://pubmed.ncbi.nlm.nih.gov/39400702/).

How long after starting Fosamax can osteonecrosis of the jaw occur?

Symptoms can appear as early as one day after starting the drug or may take several months to develop. The risk increases with longer duration of use, with notable elevations after 2-3 years and more substantially after 10 years (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56; https://pubmed.ncbi.nlm.nih.gov/39400702/).

What are the main risk factors for developing osteonecrosis of the jaw while on Fosamax?

Known risk factors include invasive dental procedures (tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (periodontal disease, anemia, coagulopathy, infection, ill-fitting dentures). Longer duration of bisphosphonate use also increases risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.